This website is intended for healthcare professionals only.

Hospital Healthcare Europe
Hospital Pharmacy Europe     Newsletter          

Search results for "" (5922)


 
Higher mean arterial pressure unlikely to prevent AKI in shock and perioperative patients
Amino acids supplement improves muscle and gut function in critically ill patients
Nirmatrelvir and ritonavir safe in pregnancy
No clear temperature threshold for infection screening in hypothermic infants
Morning physical activity linked to lowest risk of cardiovascular disease
Early Alzheimer’s disease cognitive decline slowed by lecanemab
Subcutaneous foslevodopa foscarbidopa infusion improves control in Parkinson’s disease
GSK3036656 shows bactericidal activity after 14 days in pulmonary tuberculosis
Longer rivaroxaban course reduces risk of recurrent venous thromboembolism
Sutimlimab approved in Europe for cold agglutinin haemolytic anaemia
Statin induced muscle symptoms not improved with vitamin D
Telmisartan fails to improve disease severity among patients hospitalised with COVID-19
Myocarditis rate higher in younger people following mRNA vaccination
Higher olive oil intake linked to lower CVD and all-cause mortality risk
HDL cholesterol protective role questioned
Review finds honey improves cardiometabolic risk factors
Fentanyl vaccine shows promise in animal studies
Dupixent recommended for EU approval to treat moderate to severe prurigo nodularis
Multiple sclerosis risk from anti-diabetic medication age dependent
Long-term radiotherapy reduces local breast cancer recurrence but not overall survival
Trastuzumab deruxtecan treatment of advanced gastric cancer recommended for EU approval 
Digital tumour infiltrating lymphocyte scoring predicts ICI benefit in lung cancer
Pembrolizumab with radiotherapy equal to cetuximab for advanced head and neck SCC
Anticoagulation reversal agents equally effective and safe after intracranial haemorrhage
Post-COVID-19 condition persists for at least 2 years
Baxdrostat effective in treatment-resistant hypertension
Gantenerumab fails to meet primary outcome in Alzheimer’s disease

×